SNP rs3863377 (G → A) | |||||
Case | MAF (%) | P | OR | CI | Reported MAFs 1 |
non-IBD | 32 (2.9) | Â | Â | Â | 4.0% |
IBD | 10 (1.1) | 0.004** †| 0.37 | 0.18-0-75 |  |
CD | 6 (1.1) | 0.015* †| 0.36 | 0.15-0.86 |  |
UC | 4 (1.2) | 0.075 †| 0.38 | 0.14-1.10 |  |
SNP rs56163822 , (G →T) | |||||
Case | MAF (%) | P | OR | CI | Reported MAFs 1 |
non-IBD | 20 (1.7) | Â | Â | Â | 2.2% |
IBD | 34 (3.2) | 0.027* | 1.86 | 1.06-3.25 | Â |
CD | 20 (2.9) | 0.081 | 1.74 | 0.93-3.25 | Â |
UC | 14 (3.5) | 0.036* | 2.07 | 1.03-4.13 | Â |
SNP rs7138843 , (A → T) | |||||
Case | MAF (%) | P | Â | Â | Reported MAFs 1 |
non-IBD | 17 (1.7) | Â | Â | Â | 0.9% |
IBD | 21 (2.4) | ns | Â | Â | Â |
CD | 11 (2.0) | ns | Â | Â | Â |
UC | 10 (3.0) | ns | †|  |  |
SNP rs10860603 , (G → A) | |||||
Case | MAF (%) | Â | P | Â | Reported MAFs 1 |
non-IBD | 173 (14.9) | Â | Â | Â | 20.5% |
IBD | 139 (12.9) | ns | Â | Â | Â |
CD | 90 (13.4) | ns | Â | Â | Â |
UC | 49 (12.3) | ns | Â | Â | Â |
SNP rs35724 , (G → C) | |||||
Case | MAF (%) | P | Â | Â | Reported MAFs 1 |
non-IBD | 466 (40.0) | Â | Â | Â | 40.8% |
IBD | 471 (43.8) | ns | Â | Â | Â |
CD | 299 (44.4) | ns | Â | Â | Â |
UC | 172 (43.0) | ns | Â | Â | Â |